journal article·2019-12-04Open access

Polyethyleneimine-polyethylene glycol copolymer targeted by anti-HER2 nanobody for specific delivery of transcriptionally targeted tBid containing construct

Batoul Saqafi, Fatemeh Rahbarizadeh

Abstract

The present research seeks to investigate the process of mixing targeted gene delivery and transcriptional targeting. We have conjugated Polyethylenimine polymers (PEI) and molecules of poly (ethylene glycol). The next step was covalent attachment of anti-HER2 variables domains of camelid heavy chains antibodies (VHHs) or nanobodies (Nbs) to the distal terminals of NHS-PEG3500 in PEI-PEG nanoparticles. The whole procedure yielded PEI-PEG-Nb immunoconjugates. Having determined the properties of polyplexes, steps were taken to investigate the most efficient ratio of PEI polymers to pDNA molecules (N/P) so that the greatest rate of transfection may be obtained. This immune targeted nano biopolymer could condense the gene constructs that coded a transcriptionally targeted truncated -Bid (tBid) killer gene which was controlled by the breast cancer-specific MUC1 promoter. The favourable physicochemical properties matching both the size and zeta potential were observed in engineered polyplexes. Elevated transfection efficiency in HER2 positive cell lines using Nb-modified polyplexes were shown by the results of flow cytometry as compared against non-modified particles. 1.6 and 4.8 fold higher transfection efficiencies were observed in in vitro gene expression researches which used PEI-PEG-Nb/pGL4.50 compared to the situation when native PEI polymers were utilized in both BT-474 and SK-BR-3, respectively. A 2.22 and 3.62 fold rise in the level of tBid gene expression in BT-474 and SK-BR-3 cell lines relative to unmodified PEI treated cells was the result of transfection with PEI-PEG-Nb/pMUC1-tBid, respectively. In those HER2-positive cells which were transfected by targeted polyplexes, higher levels of cell death were observed. This fact points not only to the effective targeted delivery, but it is also indicative of transcriptional targeting efficiency of tBid killer gene when its expression is controlled by MUC1 promoter.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Monoclonal and Polyclonal Antibodies Research · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Medical Sciences, Department of Medical Biotechnology, Tarbiat Modares University

References (27)

Show source-provided references
1. 10.1002/1098-2795(200007)56:3<353::AID-MRD4>3.0.CO;2-310.1002/1098-2795(200007)56:3<353::AID-MRD4>3.0.CO;2-3 ↗
2. 10.1016/S0092-8674(00)81590-110.1016/S0092-8674(00)81590-1 ↗
3. 10.1016/S0092-8674(00)81589-510.1016/S0092-8674(00)81589-5 ↗
4. 10.1074/jbc.274.2.115610.1074/jbc.274.2.1156 ↗
5. 10.1101/cshperspect.a00871410.1101/cshperspect.a008714 ↗
6. Gardlik R, Palffy R, Hodosy J, et al. Vectors and delivery systems in gene therapy. Med Sci Monit. 2005;11:RA110–RA121.
7. 10.1073/pnas.92.16.729710.1073/pnas.92.16.7297 ↗
8. 10.1023/A:101486190047810.1023/A:1014861900478 ↗
9. 10.1021/bc060077y10.1021/bc060077y ↗
10. Castan L, Silva CJd, Molina EF, et al. Comparative study of cytotoxicity and genotoxicity of commercial Jeffamines® and polyethylenimine in CHO-K1 cells. J Biomed Mater Res Part B: Appl Biomater. 2017.
11. 10.1021/bc049743q10.1021/bc049743q ↗
12. 10.1039/C7TB01046J10.1039/C7TB01046J ↗
13. 10.1016/j.msec.2017.04.11610.1016/j.msec.2017.04.116 ↗
14. 10.1016/j.jddst.2016.12.00510.1016/j.jddst.2016.12.005 ↗
15. 10.1002/jgm.38210.1002/jgm.382 ↗
16. 10.1146/annurev-biochem-063011-09244910.1146/annurev-biochem-063011-092449 ↗
17. 10.3389/fimmu.2017.0077110.3389/fimmu.2017.00771 ↗
18. 10.1016/j.yexcr.2012.03.00410.1016/j.yexcr.2012.03.004 ↗
19. 10.1038/sj.cgt.770086710.1038/sj.cgt.7700867 ↗
20. Gileadi O. Methods in molecular biology. In B Kobe, M Guss, T Huber, editors. Structural proteomics: high-throughput methods. 1st ed. Humana Press. p. 426.
21. 10.1177/088391151556900510.1177/0883911515569005 ↗
22. 10.1016/0003-9861(59)90090-610.1016/0003-9861(59)90090-6 ↗
23. 10.1021/bi00741a01910.1021/bi00741a019 ↗
24. 10.1016/j.ejps.2012.10.01610.1016/j.ejps.2012.10.016 ↗
25. 10.1159/00021777510.1159/000217775 ↗
26. Duraisamy S, Kufe T, Ramasamy S, et al. Evolution of the human MUC1 oncoprotein. Int J Oncol. 2007;31:671–677.
27. 10.1002/btpr.35310.1002/btpr.353 ↗